Alterity Therapeutics (ATHE) vs Fractyl Health (GUTS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Alterity Therapeutics (ATHE) has outperformed Fractyl Health (GUTS) over the past year, losing 22.4% versus a loss of 74.8%. Fractyl Health is the larger company by market cap ($56.1 million vs $55.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATHE | GUTS |
|---|---|---|
| Share price | $3.07 | $4.23 |
| Market cap | $55.90M | $56.11M |
| 1-day change | -7.53% | -6.42% |
| YTD return | +7.79% | -83.98% |
| 1-year return | -22.43% | -74.82% |
| 5-year return | -74.66% | — |
| EPS (TTM) | $-0.90 | $-10.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.89 | $29.34 |
| 52-week low | $2.66 | $4.14 |
| Distance from 52-week high | -47.88% | -85.58% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +331.60% | +1327.90% |
| Average volume | 16.47K | 152.04K |
| Shares outstanding | 18.21M | 13.26M |
| Employees | 11 | 100 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ATHE has outperformed GUTS by 52.4 percentage points over the past year.
About Alterity Therapeutics
ATHE stock →Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease.
Healthcare · Biotechnology · 11 employees
About Fractyl Health
GUTS stock →Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
Healthcare · Biotechnology · 100 employees
ATHE vs GUTS FAQ
Which is bigger, Alterity Therapeutics or Fractyl Health?
Fractyl Health (GUTS) is larger, with a market capitalization of $56.11M compared with $55.90M for Alterity Therapeutics (ATHE).
Which stock has performed better over the past year, ATHE or GUTS?
ATHE returned -22.43% over the past 12 months, compared with -74.82% for GUTS (price return, excluding dividends). Past performance does not predict future results.
Are Alterity Therapeutics and Fractyl Health in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.